References

  1. Data on file. © SmithKline Beecham, UK, 1996.
  2. Treister NS, Woo S-B. Topical n-docosanol for management
    of recurrent herpes labialis. Expert Opin Pharmacother. 2010;11(5):353–860.
  3. Data on file. © SmithKline Beecham, UK, 1995.
  4. Drugstore Canada and L’actualité pharmaceutique 2012 Survey on OTC Counselling and Recommendations. / The Medical Post and L’actualité médicale 2012 Survey on OTC Counselling
    and Recommendations.
  5. Abreva® (docosanol cream, 10%) Product Monograph.
    GSK Consumer Healthcare Inc. July 23, 2008.
  6. GlaxoSmithKline. Common triggers that can lead to a
    cold sore outbreak. Accessed at: http://www.abreva.ca/
    ColdSoreBasics/triggers.aspx on Feb. 27, 2012.
  1. Sacks SL, Thisted RA, Jones TM, et al. Clinical efficacy
    of topical docosanol 10% cream for herpes simplex labialis:
    a multicenter, randomized, placebo-controlled trial.
    J Am Acad Dermatol. 2001;45:222–230.
  2. Spruance SL. Semin Dermatol. 1992;11:200.
  3. Harmenberg J, Oberg B, Spruance S. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: a literature review. Acta Derm Veneriol. 2010;90:122–130.
  4. Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber
    J, Hill J, et al. High-dose, short-duration, early
    valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.
    Antimicrob Agents Chemother. 2003;47(3):1072–1080.

™/® or licensee GlaxoSmithKline
Consumer Healthcare Inc. Mississauga, Ontario L5N 6L4
©2013 GlaxoSmithKline